

Polar Capital Global Healthcare Trust PLC

06:30 29 Nov 2018

Small-cap sell-off might not be done yet, warns Polar Capital healthcare fund manager

Last month's global equities sell-off prompted a few in the City to get a bit twitchy with some of their holdings.

Not Polar Capital Global Healthcare Trust PLC (LON:PCGH) fund manager Daniel Mahony, though.

Large caps in better health, though

"We virtually did nothing last month," Mahony explains. "We've seen a few of these sell-offs and I think the worst thing you can do is react to the market."

Given the size of the drops, some have been speculating that now might be a good time to go back in, but Mahony isn't so sure, particularly when it comes to the smaller companies.

"I think you have to be careful. Valuations of some of these really racy, growth momentum names have come back but they could go a lot further."

The manager sold down some of his small- and mid-cap exposure in the run-up to the sell-off, but his caution doesn't extend to the big pharma stocks - the AstraZenecas and Mercks of this world - which make up around 85% of the portfolio.

"The large cap stocks look good value right now ... because [they] didn't get super expensive about a year ago at the racy end of the market."

Mahony is keen to stress that there is much more to his trust than just picking the biggest names in pharma and healthcare and sprinkling in some exciting small caps.

"It's not as simple as buying the ten top companies, because there's a structural change going on and there will be winners and losers. The winners could win big and the losers could lose big."

He points to Novartis and AstraZeneca - both of which he owns - which have been working hard on developing their drug pipelines, as examples of those who are getting "on the front foot".

He's a bit more fearful for companies with older drugs such as GlaxoSmithKline, which he thinks will start to come under pricing pressures in the near future.


Mahony got into fund management and analysis after a spell in research.

Having studied at Oxford and then Cambridge, he moved over to California, the "golden Mecca" for biotechs, where he worked for a drug company developing cancer treatments.

Price: 218p

Market Cap: £265.46M

1 Year Share Price Graph



June 2018 December 2018 June 2019

Share Information

Code: PCGH

Listing: LSE

52 week High Low
230.00p 197.50p

Sector: Health Care, Equipment & Services

Website:

www.polarcapitalhealthcaretrust.com

Company Synopsis:

The Polar Capital Global Healthcare Trust plc was launched in June 2010. In 2017 shareholders extended the life of the Company until 2025. It seeks to generate capital growth by investing in a global portfolio of healthcare stocks across all healthcare sub-sectors. Polar Capital's healthcare team is highly experienced with a broad and diversified skill-set and a strong track record.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

"I had an accident where I lost a year's worth of work because a freezer broke down and at that point I thought, 'you know what, I'm done with research'."

Double your money in seven years

From there, he spent two years in New York attending night classes to beef up his finance and accounting knowledge, before moving back to London to work for Morgan Stanley.

Helping him pick the winners and losers now is a team of six analysts, all of whom, like him, have a background in healthcare.

"What we're trying to do is help our clients position themselves. Previously you could own Glaxo or Astra and you'd be fine in a portfolio, but now you need to make sure you're in the right big caps.

"If you own Astra, especially if you're a private client, come and own us instead, because we'll give you diversification and we think that, by and large, we should be able to outperform any single investment over a period of time."

History would suggest that Mahony's claims have some credibility, too. The trust's stated aim is to deliver returns of 8-10% per annum, which as he points out, would almost double investors' money in seven years.

"That's what we did between 2010 and 2017, so we're just trying to repeat that."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.